# US 2019/0314498 A1 · Etanercept Formulations Stabilized with Sodium Chloride

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314498 A1
- Document ID: US20190314498A1
- Status: Published application
- Kind: A1
- Application number: 16/453,041
- Filed: 2019-06-26
- Published: 2019-10-17
- Earliest claimed: 2011-10-18
- Assignees: Coherus Biosciences, Inc.
- Applicants: Coherus Biosciences, Inc.
- Inventors: Mark MANNING; Brian MURPHY
- Web page: https://patentgrep.com/patent/US20190314498A1

## CPC

- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.

## Claims

### Claim 1

A stable aqueous etanercept formulation comprising about 25 to about 75 mg/ml of etanercept, wherein the etanercept is stabilized by a stabilizing component having about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and one or more amino acids selected from the group consisting of L-serine, sodium glutamic acid, alanine, glycine, and lysine, wherein the stable aqueous etanercept formulation is free of arginine.

### Claim 2 (depends on 1)

The formulation of claim 1 wherein the formulation elicits long term storage stability as characterized by at least one of:
SEC analysis at M3 or T2 or T4 of: monomer content greater than about 90%; aggregates content of less than about 3 wt. %; and fragment 3 content less than about 5 wt. %.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein etanercept is at a concentration of 50 mg/ml.

### Claim 4 (depends on 1)

The formulation of claim 1, further comprising an aqueous buffer.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein the aqueous etanercept formulation has a pH of about 6.0 to about 6.6.

### Claim 6 (depends on 1)

The formulation of claim 1, wherein the stable aqueous etanercept formulation elicits long term storage stability as characterized by: an HIC analysis at M3 or T2 or T4 wherein the amount of the stable aqueous etanercept formulation represented by peak 2 of the HIC chromatogram is greater than or equal to 95 wt. %; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the formulation represented by peak 3 is less than or equal to about 3 wt. %.

### Claim 7 (depends on 1)

The formulation of claim 1, wherein the stable aqueous etanercept formulation has no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 μm.

### Claim 8 (depends on 1)

The formulation of claim 1, wherein the stable aqueous formulation formulation elicits long term storage stability as characterized by at least one of: HIC analysis at M3 or T2 or T4 wherein the amount of the formulation represented by peak 1 of the HIC chromatogram is less than about 3 wt. %; the amount of the formulation represented by peak 2 of the HIC chromatogram is greater than 80 wt. %; and the amount of the formulation represented by peak 3 of the HIC chromatogram is less than about 20 wt. %.

### Claim 9 (depends on 1)

The formulation of claim 1, wherein the stable aqueous formulation is free of cysteine.

### Claim 10 (depends on 1)

The formulation of claim 1, wherein the stable aqueous formulation consists of about 50 mg/ml of etanercept stabilized by an aqueous buffer and about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and glycine or lysine.

### Claim 11 (depends on 1)

The formulation of claim 1, wherein the stable aqueous formulation consists of about 50 mg/ml of etanercept stabilized by an aqueous citrate buffer and about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and glycine or lysine.

### Claim 12 (depends on 1)

The formulation of claim 1, wherein the stable aqueous formulation consists of about 50 mg/ml of etanercept stabilized by an aqueous citrate buffer and about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and lysine.

### Claim 13

A method of treating a subject in need of treatment by injection of etanercept comprising administering to the subject a stable aqueous etanercept composition comprising 25 to 75 mg/ml etanercept, wherein the etanercept is stabilized by a stabilizing component having about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and one or more amino acids selected from the group consisting of L-serine, sodium glutamic acid, alanine, glycine, and lysine, wherein the stable aqueous etanercept composition is free of arginine.

### Claim 14 (depends on 13)

The method of claim 13, comprising administering 25-100 mg etanercept per dose to the subject.

### Claim 15 (depends on 13)

The method of claim 13, comprising injecting the stable aqueous etanercept composition subcutaneously or intramuscularly.

### Claim 16 (depends on 13)

The method of claim 13, wherein the stable aqueous etanercept composition consists of about 50 mg/ml of etanercept stabilized by an aqueous buffer and about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and glycine or lysine.

### Claim 17 (depends on 13)

The method of claim 13, wherein the stable aqueous etanercept composition consists of about 50 mg/ml of etanercept stabilized by an aqueous citrate buffer and about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and glycine or lysine.

### Claim 18 (depends on 13)

The method of claim 13, wherein the stable aqueous etanercept composition consists of about 50 mg/ml of etanercept stabilized by an aqueous citrate buffer and about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and lysine.

### Claim 19 (depends on 13)

The method of claim 13, wherein subject suffers from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or a psoriasis.

### Claim 20

A vial, syringe, or injector pen containing a stable aqueous etanercept composition comprising 25 to 75 mg/ml etanercept, wherein the etanercept is stabilized by an aqueous buffer and a stabilizing component having about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and one or more amino acids selected from the group consisting of L-serine, sodium glutamic acid, alanine, glycine, and lysine, wherein the stable aqueous etanercept composition is free of arginine, wherein the stable aqueous etanercept composition has a pH of about 6.0 to about 6.6.
